March 27, 2012, VANCOUVER, CANADA – iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that Andrew Rae, President & CEO, has been invited to speak at the Drug Development Forum at the Retinal Physician Symposium 2012 (RPS). RPS will be held March 28-31, 2012 in Miami, FL. The forum will take place on the first day of the Symposium, Wednesday, March 28, from 3:00 PM to 7:00 PM ET.
Mr. Rae will be co-presenting on the panel entitled Macular Edema Today and Tomorrow, along with: John Snisarenko, Genentech’s Vice President of Sales and Marketing for Lucentis; David Brown, MD, Retina Consultants of Houston; and George Yancopoulos, MD, PhD, Executive Vice President, Chief Scientific Officer and President, Regeneron Research Laboratories. The Specific topic to be covered by Mr. Rae will be How to Raise Money for Small Companies in the “Edema Space”.
RPS is a leading ophthalmology conference focused on current and future treatment strategies in medical and surgical retina care, as well as the latest clinical trial data in diabetic macular edema, vein occlusion, and age-related macular degeneration.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol “ICO”. For more information, visit the Company website at: icotherapeutics.cdmail.biz.
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.